Ahmed E Enayetallah
Overview
Explore the profile of Ahmed E Enayetallah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kakiuchi-Kiyota S, Koza-Taylor P, Mantena S, Nelms L, Enayetallah A, Hollingshead B, et al.
Toxicol Sci
. 2013 Dec;
138(1):234-48.
PMID: 24336348
Development of LNA gapmers, antisense oligonucleotides used for efficient inhibition of target RNA expression, is limited by non-target mediated hepatotoxicity issues. In the present study, we investigated hepatic transcription profiles...
2.
Davis A, Wiegers T, Roberts P, King B, Lay J, Lennon-Hopkins K, et al.
Database (Oxford)
. 2013 Nov;
2013:bat080.
PMID: 24288140
Improving the prediction of chemical toxicity is a goal common to both environmental health research and pharmaceutical drug development. To improve safety detection assays, it is critical to have a...
3.
OConnor M, Koza-Taylor P, Campion S, Aleksunes L, Gu X, Enayetallah A, et al.
Toxicol Appl Pharmacol
. 2013 Oct;
274(1):156-67.
PMID: 24126418
Pretreatment of mice with a low hepatotoxic dose of acetaminophen (APAP) results in resistance to a subsequent, higher dose of APAP. This mouse model, termed APAP autoprotection was used here...
4.
Enayetallah A, Puppala D, Ziemek D, Fischer J, Kantesaria S, Pletcher M
BMC Pharmacol Toxicol
. 2013 Sep;
14:46.
PMID: 24010585
Drug-induced cardiac toxicity has been implicated in 31% of drug withdrawals in the USA. The fact that the risk for cardiac-related adverse events goes undetected in preclinical studies for so...
5.
Enayetallah A, Ziemek D, Leininger M, Randhawa R, Yang J, Manion T, et al.
PLoS One
. 2011 Nov;
6(11):e27009.
PMID: 22073239
Triglyceride accumulation is associated with obesity and type 2 diabetes. Genetic disruption of diacylglycerol acyltransferase 1 (DGAT1), which catalyzes the final reaction of triglyceride synthesis, confers dramatic resistance to high-fat...
6.
Enayetallah A, Luria A, Luo B, Tsai H, Sura P, Hammock B, et al.
J Biol Chem
. 2008 Nov;
283(52):36592-8.
PMID: 18974052
Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with two catalytic domains: a C-terminal epoxide hydrolase domain and an N-terminal phosphatase domain. Epidemiology and animal studies have attributed a variety...
7.
Sura P, Sura R, Enayetallah A, Grant D
J Histochem Cytochem
. 2008 Mar;
56(6):551-9.
PMID: 18319271
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid, which function in the brain to regulate cerebral blood flow and protect against ischemic brain injury. EETs are converted by...
8.
Enayetallah A, French R, Grant D
J Mol Histol
. 2006 Sep;
37(3-4):133-41.
PMID: 16957870
Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with a C-terminal epoxide hydrolase activity and an N-terminal phosphatase activity. Arachidonic acid epoxides, previously suggested to be involved in apoptosis, oncogenesis...
9.
Enayetallah A, Grant D
Biochem Biophys Res Commun
. 2006 Jan;
341(1):254-60.
PMID: 16414022
Soluble epoxide hydrolase (sEH) is highly expressed in human liver and contains a C-terminal epoxide hydrolase activity and an N-terminal phosphatase activity. Endogenous C-terminal hydrolase substrates include arachidonic acid epoxides,...
10.
Enayetallah A, French R, Barber M, Grant D
J Histochem Cytochem
. 2005 Nov;
54(3):329-35.
PMID: 16314446
Soluble epoxide hydrolase (sEH) is a phase-I xenobiotic metabolizing enzyme having both an N-terminal phosphatase activity and a C-terminal epoxide hydrolase activity. Endogenous hydrolase substrates include arachidonic acid epoxides, which...